Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Shares in Novavax almost doubled after Sanofi struck a licensing deal worth up to $1.2bn to commercialise ...
Novavax on Friday said it had struck a licensing deal worth at least $1.2 billion with Sanofi for its COVID-19 vaccine in ...
Sanofi will pay vaccine maker Novavax $500 million and take a small equity stake in the Maryland-based company as part of a broad COVID-19 shot alliance, the companies announced Friday. Through the ...
LONDON — Novavax, the beleaguered maker of a Covid-19 vaccine, just got a boost of its own. The French pharma company Sanofi on Friday said it had reached a licensing deal to sell Novavax’s ...
The deal will allow Novavax to lift its "going concern" warning, which it first issued in 2023 due to having "substantial ...
Novavax Inc. NVAX-Q on Friday said it had struck a licensing deal worth at least US$1.2-billion with Sanofi SNY-Q for its COVID-19 vaccine in exchange for a stake that valued the U.S. biotech firm ...
Novavax shares (NVAX) surged after the vaccine maker said it had struck a licensing deal worth up to $1.4 billion with Sanofi (SNY, FR:SAN). Novavax shares were up 133% in recent trading at $10.11.
Novavax Inc. shares surged after the company signed a $1.2 billion licensing agreement with Sanofi that includes commercializing a combined Covid-19 and flu shot. Novavax will receive $500 million in ...
(Bloomberg) -- Novavax Inc. shares surged after the company signed a $1.2 billion licensing agreement with Sanofi that includes commercializing a combined Covid-19 and flu shot. Most Read from ...
LONDON — Novavax, the beleaguered maker of a Covid-19 vaccine, just got a boost of its own. The French pharma company Sanofi on Friday said it had reached a licensing deal to sell Novavax’s ...